Uniqure N V (QURE) Gross Profit Margin starting from the first quarter 2026 to first quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Uniqure N v   (NASDAQ: QURE)


Uniqure N V 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QURE Gross Profit Margin (Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2 		(Mar 31 2025)
Q1
Y / Y Revenue Change 127.31 %
Seq. Revenue Change -36.03 %
Revenue In Millions $3.56
Gross Profit Margin 93.85 %
Gross Profit Margin Total Ranking # 262
Gross Profit In Millions $3.34
Y / Y Gross Profit Change 144.01 %
Seq. Gross Profit Change -34.87 %


Commenting First Quarter 2026 Gross Profit Margin
Uniqure N v increased Gross Profit Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -34.87 % and Revenue by -36.03 %. Gross Profit Margin in Q1 was 93.85 %, above company average.


Observing first quarter 2026 results within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 262, from total ranking in the previous quarter at 317.
Learn about Gross Margin
QURE's Gross Profit Margin first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 24
Healthcare Sector # 40
Overall # 261

Gross Profit Margin Statistics
High Average Low
99.57 % 86.55 % 40.58 %
(Dec 31 2022)   (Sep 30 2022)


QURE Gross Income Trends • More of QURE's Profitabilty Ratios • QURE Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
QURE's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
QURE's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for QURE's Competitors
Gross Profit Margin Profit Margin for Uniqure N V 's Suppliers
Gross Profit Margin Profit Margin for QURE's Customers

You may also want to know
QURE's Annual Growth Rates QURE's Profitability Ratios QURE's Asset Turnover Ratio QURE's Dividend Growth
QURE's Roe QURE's Valuation Ratios QURE's Financial Strength Ratios QURE's Gross Profit Growth
QURE's Roa QURE's Inventory Turnover Ratio QURE's Growth Rates QURE's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2026 MRQ Gross ProfitMar 31 2026 MRQ Revenue
Zai Lab Limited  99.98 %$ 99.591  Millions$ 99.611  Millions
Hcw Biologics Inc   99.83 %$ 6.532  Millions$ 6.543  Millions
Lexicon Pharmaceuticals Inc   99.49 %$ 20.994  Millions$ 21.102  Millions
Ptc Therapeutics inc   99.34 %$ 270.751  Millions$ 272.551  Millions
Omeros Corporation  99.29 %$ 82.452  Millions$ 83.039  Millions
Cytokinetics Incorporated  99.17 %$ 19.195  Millions$ 19.355  Millions
Ionis Pharmaceuticals Inc   98.79 %$ 243.108  Millions$ 246.091  Millions
Kura Oncology Inc   98.57 %$ 18.003  Millions$ 18.265  Millions
Verastem Inc   98.51 %$ 18.392  Millions$ 18.671  Millions
Travere Therapeutics Inc   98.47 %$ 125.249  Millions$ 127.199  Millions
Corcept Therapeutics Inc  98.25 %$ 162.020  Millions$ 164.903  Millions
Crinetics Pharmaceuticals Inc   98.14 %$ 10.534  Millions$ 10.734  Millions
Silence Therapeutics Plc  97.39 %$ 0.411  Millions$ 0.422  Millions
Karyopharm Therapeutics Inc   96.16 %$ 33.721  Millions$ 35.066  Millions
Scienture Holdings Inc   95.61 %$ 0.054  Millions$ 0.056  Millions
Rafael Holdings Inc  95.53 %$ 0.171  Millions$ 0.179  Millions
Tao Synergies Inc   95.52 %$ 0.371  Millions$ 0.389  Millions
Ardelyx inc   94.91 %$ 89.662  Millions$ 94.473  Millions
Bridgebio Pharma Inc   94.89 %$ 184.576  Millions$ 194.515  Millions
Gyre Therapeutics Inc   94.55 %$ 21.292  Millions$ 22.519  Millions
Jaguar Health Inc   94.29 %$ 19.114  Millions$ 20.272  Millions
Milestone Pharmaceuticals Inc   94.12 %$ 0.224  Millions$ 0.238  Millions
Vanda Pharmaceuticals Inc   93.89 %$ 48.559  Millions$ 51.718  Millions
Uniqure N v   93.85 %$ 3.343  Millions$ 3.562  Millions
Agios Pharmaceuticals Inc   93.64 %$ 19.427  Millions$ 20.746  Millions
Zevra Therapeutics Inc   93.46 %$ 27.107  Millions$ 29.004  Millions
Adc Therapeutics Sa  92.94 %$ 19.378  Millions$ 20.851  Millions
Apellis Pharmaceuticals Inc   92.55 %$ 248.295  Millions$ 268.295  Millions
Kalvista Pharmaceuticals Inc   92.44 %$ 37.773  Millions$ 40.863  Millions
Axsome Therapeutics Inc   92.30 %$ 176.478  Millions$ 191.203  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.